title: [Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma].
abstract: The paper presents a detailed review of the data available in the literature on the treatment of cryoglobulinemic vasculitis and some forms of B-cell non-Hodgkin lymphoma caused by hepatitis C virus. It shows treatment successes associated with the use of current combined antiviral therapy (interferon-alpha and ribavirin) and its combination with anti-CD20 monoclonal antibodies (rituximab). The combined therapy with rituximab and antiviral drugs allows a radical improvement of prognosis in nearly 50% of patients. Remaining treatment problems and new drug prospects are discussed.
authors.forename: T M
authors.initials: TM
authors.lastname: Ignatova
authors.forename: N A
authors.initials: NA
authors.lastname: Mukhin
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003449:Cryoglobulinemia / Q000188:drug therapy* / Q000821:virology; D004359:Drug Therapy, Combination; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000821:virology; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D000069283:Rituximab; D014657:Vasculitis / Q000188:drug therapy* / Q000821:virology
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin; D000069283:Rituximab